Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-01
2007-05-01
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000, C530S300000, C530S350000, C530S363000
Reexamination Certificate
active
10094401
ABSTRACT:
Compositions comprising non-naturally occurring serum albumin binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to albumin. Preferred serum albumin binding peptides having a high affinity for human serum albumin are particularly disclosed.
REFERENCES:
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5538897 (1996-07-01), Yates, III et al.
patent: 5767243 (1998-06-01), Lichenstein et al.
patent: 5780594 (1998-07-01), Carter
patent: 5830858 (1998-11-01), Rosenthal
patent: 5834318 (1998-11-01), Buettner
patent: 5958736 (1999-09-01), Ståhl et al.
patent: 6177542 (2001-01-01), Ruoslahti et al.
patent: 6919424 (2005-07-01), Rondon et al.
patent: 2002/0019350 (2002-02-01), Levine et al.
patent: 2002/0146750 (2002-10-01), Hoogenboon et al.
patent: 2002/0164667 (2002-11-01), Alitalo et al.
patent: 2003/0069395 (2003-04-01), Sato et al.
patent: 2003/0104591 (2003-06-01), Murray
patent: 2004/0009534 (2004-01-01), Sato et al.
patent: 2004/0071705 (2004-04-01), Sato et al.
patent: 2005/0250700 (2005-11-01), Sato et al.
patent: 0 395 918 (1990-11-01), None
patent: 0 395918 (1990-11-01), None
patent: WO 01/01743 (1991-02-01), None
patent: WO 91/01743 (1991-02-01), None
patent: WO 92/12236 (1992-07-01), None
patent: WO 00/37501 (2000-06-01), None
patent: WO 01/45746 (2001-06-01), None
patent: WO 03/074005 (2003-09-01), None
Sequence Alignment Results for SEQ ID No. 4, p. 2.
Sato et al. Biotechnology Prog. 2002, 18, 182-192.
Briggs et al. (European Journal of Cancer, 1993, vol. 29A, No. 2, pp. 230-237).
Adams, P. et al., “Heme-Peptide/Protein Interactions: The Binding of Heme Octa and Undecapeptides, and Microperoxidase-8 and -11, to Human Serum Albumin,”J. Inorg. Biochem., 37:91-103, (1989).
Arakawa, T. and Kita, Y., “Stabilizing Effects of Caprylate and acetyltryptophanate on Heat-Induced Aggregation of Bovine Serum Albumin,”Biochim. Biophy. Acta, 1479:32-36, (2000).
Chhabra, S. et al., “An Appraisal of New Variants of Dde Amine Protecting Group for Solid Phase Peptide Synthesis,”Tetrahedron Lett., 39:1603-1606, (1998).
Cheruvallath, V. et al., “The effect of Octanoic Acid on the Binding of the Enantiomers of Ibuprofen and Naproxen to Human Serum Albumin: A Chromatographic Implication,”Pharm. Res., 13:173-178, (1996).
Hollon, T., “HGS Targets Patent-Expiring Drugs,”Nat. Biotechnol., 18:1238-1239, (2000).
Kobayashi, K. et al., “The Development of Recombinant Human Serum Albumin,”Ther. Apher, 2:257-262, (1998).
Kragh-Hansen, U., “Octanoate Binding to the Indole- and Benzodiazepine-Binding Region of Human Serum Albumin,”Biochem. J., 273:641-644, (1991).
Luik, A. et al., “Study of Human Serum Albumin Structure by Dynamic Light Scattering: Two Types of Reactions Under Different pH and Interaction With Physiologically Active Compounds,”Spectrochim. Acta Part A, 54:1503-1507, (1998).
Mahany, T. et al., “Studies on the Affinity Chromatography of Serum Albumins from Human and Animal Plasmas,”Comp. Biochem, Physiol., 68B:319-323, (1981).
Merrifield, R., “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,”J. Am. Chem. Soc., 85:2149-2154, (1963).
Norde, W. and Giacomelli, C., “BSA Structural Changes During Homomolecular Exchange Between the Adsorbed and the Dissolved States,”J. Biotechnol., 79:259-268, (2000).
Pingali, A. et al., “Peptides as Affinity Surfaces for Protein Purification,”J. Mol. Recognit., 9:426-432, (1996).
Ross, P. et al., “Thermal Stability of Human Albumin Measured by Differential Scanning Calorimetry,”Vox Sang., 47:19-27, (1984).
Saeed, M. et al., “Blood Pool MR Contrast Agents for Cardiovascular Imaging,”J. Magn. Reson. Imaging, 12:890-898, (2000).
Seabold, J., “Radionuclide Venography and Labeled Platelets in Deep Venous Thrombosis,”Semin. Nucl. Med., 31:124-128, (2001).
Shani, M. et al., “Expression of Human Serum Albumin in the Milk of Transgenic Mice,”Transgenic Res., 1:195-208, (1992).
Shrake, A. et al., “Thermal Stability of Human Albumin Measured by Differential Scanning Calorimetry,”Vox Sang., 47:7-18, (1984).
Sijmons, P. et al., “Production of Correctly Processed Human Serum Albumin in Transgenic Plants,”Biotechnology, 8:217-221, (1990).
Yeh, P. et al., “Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate,”Proc. Natl. Acad. Sci. USA, 89:1904-1908, (1992).
Szekerke, M. et al., “A New Approach to the Study of the Contribution of Peptide Carriers to Antitumor Activity: Binding of the Peptide Moiety to Human Serum Albumin,”FEBS Letters, 44:160-163, (1974).
Akerstrom et al., “Definition of IgG- and Albumin-binding Regions of Streptococcal Protein G*”.Journal of Biological Chemistry262(28):13388-13391 (1987).
Burger et al. “Pre-Clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) in Human Tumor Xenografts in Vivo”International Journal of Cancer92:718-724 (2001).
Sato et al., “Development of Mammalian Serum Albumin Affinity Purification Media by Phage Display.”Biotechnol. Prog. 18:182-192 (2002).
Venerando et al., “Interactions of Ganglioside GM1with Human and Fetal Calf Sera Formation of Ganglioside-Serum Albumin Complexes”,Biochimica et Biophysica Acta692: 18-26 (1982).
Yousif et al., “Staphylococcal Neutral Phosphatase: A highly cataonic molecule with binding properties for immunoglobulin”,APMIS102: 891-900 (1994).
U.S. Appl. No. 60/331,352, by inventors Aaron K. Sato, Arthur C. Ley and Edward H. Cohen, filed Feb. 11, 2002.
U.S. Appl. No. 60/292,975, by inventors Aaron K. Sato, Arthur C. Ley and Edward H. Cohen, filed May 23, 2001.
Birn H et al. “Cubilin is an albumin binding protein important for renal tubular albumin reabsorption”The Journal of Clinical Investigation, vol. 105, No. 10:pp. 1353-1361 (2000).
Cuozzo J W et al. “Competition between glutathione and protein thiols for disulphide-bond formation”Nature Cell Biology, vol. 1, No. 3:pp. 130-135 (1999).
Mehta A I et al “Biomarker Amplification by Serum Carrier Protein Binding”Disease Markers, vol. 19, No. 1:pp. 1-10 (2003).
Rajkovic Vvan A Erefili Valiontis et al. “Direct quantitation of growth hormone binding protein in human serum by a ligand immunofunctional assay: Comparison with immunoprecipitation and chromatographic methods”Journal of Clinical Endocrinology and Metabolism, vol. 78, No. 3:pp. 772-777 (1994).
Sjobring U “Isolation and molecular characterization of a novel albumin-binding protein from groupG streptococci” Infection and Immunity, American Society of Microbiology, vol. 60, No. 9::pp. 3601-3608 (1992).
Supplementary Partial European Search Report (Oct. 18, 2005).
Sequence Alignment Results for SEQ ID No. 4, p. 2 dated Apr. 8, 2005 from U.S. Appl. No. 10/094,401.
Robert C. Ladner, “Constrained peptides as binding entities,” TIBTECH, Oct. 13, 1995: 426-430.
Cohen Edward H.
Ley Arthur C.
Sato Aaron K.
Cook Lisa V
Dyax Corp.
Le Long V.
LandOfFree
Serum albumin binding moieties does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serum albumin binding moieties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serum albumin binding moieties will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3800502